Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$118.13

0.86 (0.73%)

, ABBV

AbbVie

$63.07

0.25 (0.40%)

15:04
10/02/16
10/02
15:04
10/02/16
15:04

Janssen reports Phase 3 data on guselkumab in psoriasis, says shows superiority

Johnson & Johnson's (JNJ) Janssen announced findings from the first of three pivotal Phase 3 studies evaluating guselkumab, an anti-interleukin-23 monoclonal antibody in development for the treatment of adults with moderate to severe plaque psoriasis. Data from the VOYAGE 1 trial showed significantly higher proportions of patients receiving guselkumab achieved cleared/minimal disease compared with patients receiving placebo, as defined by at least a 90 percent improvement in the Psoriasis Area Severity Index and an Investigator's Global Assessment score of cleared or minimal disease at week 16, the study co-primary endpoints. The VOYAGE 1 trial also included an active comparator arm evaluating guselkumab versus AbbVie's (ABBV) Humira, and showed the superiority of guselkumab across major study endpoints and through 48 weeks of treatment. These data were presented for the first time at the European Academy of Dermatology and Venereology Congress. Specifically, in VOYAGE 1, the co-primary endpoints were met at week 16, with 85.1 percent of patients receiving guselkumab 100 mg at weeks 0 and 4 and then every eight weeks achieving cleared or minimal disease compared with 6.9 percent of patients receiving placebo. Nearly three-quarters of patients receiving guselkumab -- 73.3 percent -- achieved a PASI 90 response, or near complete skin clearance, compared with 2.9 percent of patients receiving placebo. All major secondary endpoints in VOYAGE 1 achieved statistical significance in comparisons of guselkumab versus adalimumab administered subcutaneously at weeks 0, 1 and then 40 mg every other week. At week 16, following three injections of guselkumab and ten injections of adalimumab, significantly higher proportions of patients receiving guselkumab achieved IGA 0/1 and PASI 90 -- 85.1 percent and 73.3 percent, respectively -- compared with patients receiving adalimumab -- 65.9 percent and 49.7 percent, respectively. At week 24, the proportion of patients who achieved a PASI 90 response was significantly higher in the guselkumab group compared with the adalimumab group -- 80.2 percent vs. 53.0 percent, respectively. Higher levels of skin clearance among the guselkumab group continued through weeks 24 and 48, with significantly more patients receiving guselkumab achieving IGA 0/1 and PASI 90, as well as measures of full skin clearance compared with adalimumab. The Dermatology Life Quality Index assessed the impact of disease and disease improvement following therapy on study participants' quality of life. At week 24, a score of 0/1, indicating no impact of psoriasis on health-related quality of life, was achieved by 60.9 percent of patients receiving guselkumab compared with 39.5 percent of patients receiving adalimumab. Guselkumab-treated patients also showed substantial improvement at week 48 with 62.5 percent scoring a DLQI of 0/1 compared with 38.9 percent of adalimumab-treated patients. Through week 16 of the study, the placebo-controlled period, serious AEs were reported in 1.7 percent of patients receiving placebo, 2.4 percent of patients receiving guselkumab and 1.8 percent of patients receiving adalimumab. Through week 48 of the study, the proportions of patients reporting at least one AE were comparable between guselkumab -- 73.9 percent -- and adalimumab -- 74.5 percent; the proportions of patients reporting serious AEs were also similar for guselkumab -- 4.9 percent -- and adalimumab -- 4.5 percent. Serious infections occurred in two patients receiving guselkumab and three patients receiving adalimumab. Through week 48, there was one myocardial infarction in each of the guselkumab and adalimumab treatment groups, and two solid malignancies -- one prostate and one breast cancer -- were reported in patients receiving guselkumab.

JNJ

Johnson & Johnson

$118.13

0.86 (0.73%)

ABBV

AbbVie

$63.07

0.25 (0.40%)

  • 04

    Oct

  • 07

    Oct

  • 18

    Oct

  • 06

    Nov

JNJ Johnson & Johnson
$118.13

0.86 (0.73%)

08/18/16
UBSW
08/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson remains a top large cap pick, says UBS
UBS analyst Matt Miksic said Johnson & Johnson remains a top large cap diversified pick for the year. The analyst said yesterday's court ruling that invalidated the company's Remicade patent was expected and could delay the Q4 biosimilar launch but its robust pharma pipeline remains under-appreciated and should make up the difference. He said he continues to see further clarity regarding potential U.S. biosimilar competition for Remicade as positive for the stock. Miksic reiterated his Buy rating and $137 price target on Johnson & Johnson shares.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
ABBV AbbVie
$63.07

0.25 (0.40%)

09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
09/02/16
09/02/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AbbVie (ABBV) initiated with an Outperform at Raymond James. 2. Spark Therapeutics (ONCE) initiated with a Buy at Stifel. 3. Cornerstone OnDemand (CSOD) initiated with an Overweight at Piper Jaffray. 4. UR-Energy (URG) initiated with an Outperform at FBR Capital. 5. Energy Transfer Equity (ETE) reinstated with an Overweight at JPMorgan. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/01/16
RAJA
09/01/16
INITIATION
Target $82
RAJA
Outperform
AbbVie initiated with an Outperform at Raymond James
Target $82.
07/14/16
JEFF
07/14/16
NO CHANGE
JEFF
AbbVie remains Jefferies' Top Pick in Global Pharma
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his firm's Top Pick in Global Pharmaceuticals, followed by Eli Lilly (LLY), Novartis (NVS), GlaxoSmithKline (GSK) and Zoetis (ZTS). The analyst this morning upgraded GSK to Buy from Hold. Holford also remains positive on Roche (RHHBY), Abbott (ABT) and Pfizer (PFE). The analyst's least preferred names are Novo Nordisk (NVO), Johnson & Johnson (JNJ) and Merck (MRK). The Q2 earnings season offers "few clear beat and raise" stories and looks weakest for AstraZeneca (AZN) against preliminary consensus, Holford tells investors in a pre-earnings research note.

TODAY'S FREE FLY STORIES

LLY

Eli Lilly

$68.22

2.25 (3.41%)

14:48
12/02/16
12/02
14:48
12/02/16
14:48
Recommendations
Eli Lilly analyst commentary  »

Eli Lilly expanded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 15

    Dec

P

Pandora

$12.90

1.4152 (12.33%)

, SIRI

Sirius XM

$4.56

-0.015 (-0.33%)

14:47
12/02/16
12/02
14:47
12/02/16
14:47
Periodicals
Pandora advisers said to talk to possible suitors, Bloomberg says »

Bloomberg added that…

P

Pandora

$12.90

1.4152 (12.33%)

SIRI

Sirius XM

$4.56

-0.015 (-0.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIBR

Oi S.A.

14:47
12/02/16
12/02
14:47
12/02/16
14:47
Periodicals
Oi could scrap restriction on debt-for-equity swap, Reuters says »

Brazil's Oi could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVTB

PrivateBancorp

$48.78

2 (4.28%)

, CM

CIBC

$81.64

0.26 (0.32%)

14:41
12/02/16
12/02
14:41
12/02/16
14:41
Hot Stocks
Alpine Associates opposes PrivateBancorp's acquisition by CIBC »

Alpine Associates…

PVTB

PrivateBancorp

$48.78

2 (4.28%)

CM

CIBC

$81.64

0.26 (0.32%)

KRE

SPDR S&P Regional Banking ETF

$53.05

-0.415 (-0.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

BPMX

BioPharmX

$0.38

0.0729 (23.52%)

14:38
12/02/16
12/02
14:38
12/02/16
14:38
Hot Stocks
Breaking Hot Stocks news story on BioPharmX »

Vivo Capital VIII reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$118.87

0.36 (0.30%)

14:37
12/02/16
12/02
14:37
12/02/16
14:37
Hot Stocks
Celgene agrees to complete acquisition of Acetylon »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

  • 06

    Dec

KVHI

KVH Industries

$10.85

-0.05 (-0.46%)

14:35
12/02/16
12/02
14:35
12/02/16
14:35
Hot Stocks
KVH Industries names Donald Reilly CFO »

KVH Industries announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWPH

GW Pharmaceuticals

$109.28

-2.37 (-2.12%)

14:35
12/02/16
12/02
14:35
12/02/16
14:35
Options
GW Pharmaceuticals put volume heavy and directionally bearish »

Bearish flow noted in GW…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

IWM

iShares Trust Russell 2000 Index Fund

$130.69

-0.28 (-0.21%)

, RUT

Russell 2000 Index

14:23
12/02/16
12/02
14:23
12/02/16
14:23
Technical Analysis
On The Fly: Weekly technical notes for the Russell 2000 »

The index at time of…

IWM

iShares Trust Russell 2000 Index Fund

$130.69

-0.28 (-0.21%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MHK

Mohawk

$189.72

-1.76 (-0.92%)

14:21
12/02/16
12/02
14:21
12/02/16
14:21
Recommendations
Mohawk analyst commentary  »

Mohawk a buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
12/02/16
12/02
14:16
12/02/16
14:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:16
12/02/16
12/02
14:16
12/02/16
14:16
Technical Analysis
NASDAQ market internals summary »

Volume is heavier than…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLD

Sears

$13.20

0.32 (2.48%)

14:15
12/02/16
12/02
14:15
12/02/16
14:15
Options
Sears put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

14:15
12/02/16
12/02
14:15
12/02/16
14:15
General news
Fedspeak will be compressed next week »

Fedspeak will be…

EDU

New Oriental Education

$47.96

-1.03 (-2.10%)

14:08
12/02/16
12/02
14:08
12/02/16
14:08
Periodicals
New Oriental Education engaged in college application fraud, Reuters says »

Former and current…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$219.50

-0.07 (-0.03%)

, SPX

S&P 500

$2,190.69

-0.39 (-0.02%)

14:07
12/02/16
12/02
14:07
12/02/16
14:07
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX)…

SPY

SPDR S&P 500 ETF Trust

$219.50

-0.07 (-0.03%)

SPX

S&P 500

$2,190.69

-0.39 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:05
12/02/16
12/02
14:05
12/02/16
14:05
General news
Oil rallies while equities stall »

Stocks have stalled out,…

TITN

Titan Machinery

14:02
12/02/16
12/02
14:02
12/02/16
14:02
Downgrade
Titan Machinery rating change  »

Titan Machinery…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SON

Sonoco Products

$52.74

-1.035 (-1.92%)

, BRK.A

Berkshire Hathaway

$238,530.00

-1291 (-0.54%)

14:01
12/02/16
12/02
14:01
12/02/16
14:01
Hot Stocks
Sonoco to invest $20M in new Atlanta packaging center to support Duracell ops »

Sonoco (SON) announced it…

SON

Sonoco Products

$52.74

-1.035 (-1.92%)

BRK.A

Berkshire Hathaway

$238,530.00

-1291 (-0.54%)

BRK.B

Berkshire Hathaway

$159.07

-1.05 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 02

    Dec

EDU

New Oriental Education

$48.06

-0.93 (-1.90%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Hot Stocks
Breaking Hot Stocks news story on New Oriental Education »

New Oriental down over 5%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EDU

New Oriental Education

$48.06

-0.93 (-1.90%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Periodicals
Breaking Periodicals news story on New Oriental Education »

Standards council to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYCC

ClubCorp

$13.40

0.2 (1.52%)

14:00
12/02/16
12/02
14:00
12/02/16
14:00
Options
Call buyer opens the largest open interest block in ClubCorp options »

Call buyer opens the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:00
12/02/16
12/02
14:00
12/02/16
14:00
General news
NY Fed accepted $167.88 B in daily reverse repos »

NY Fed accepted $167.88 B…

SBUX

Starbucks

$58.51

0.54 (0.93%)

13:51
12/02/16
12/02
13:51
12/02/16
13:51
Hot Stocks
Starbucks in 'capable hands' after 'surprising' CEO change, analysts say »

Shares of Starbucks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

TOT

Total

$47.82

0.07 (0.15%)

, RDS.A

Royal Dutch Shell

$52.01

0.225 (0.43%)

13:50
12/02/16
12/02
13:50
12/02/16
13:50
Periodicals
Obama expected to sign bill extending Iran sanctions, Reuters reports »

White House says…

TOT

Total

$47.82

0.07 (0.15%)

RDS.A

Royal Dutch Shell

$52.01

0.225 (0.43%)

BP

BP

$35.56

0.17 (0.48%)

XOM

Exxon Mobil

$87.36

0.12 (0.14%)

CVX

Chevron

$113.34

0.05 (0.04%)

COP

ConocoPhillips

$48.17

-0.05 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

  • 13

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.